



Advances in the Pathobiology, Diagnosis and Treatment of Chronic Myeloid Neoplasms

Guest Editors:

Dr. Luis Colomo

Hematopathology Section,
Pathology Department, Hospital
del Mar, 08003 Barcelona, Spain

Dr. Xavier Calvo

Laboratori de Citologia
Hematològica, Servei de
Patologia, Grup de Recerca
Translacional en Neoplàsies
Hematològiques (GRETNHE),
Hospital del Mar Research
Institute (IMIM), 08003 Barcelona,
Spain

Deadline for manuscript
submissions:

closed (31 July 2021)

Message from the Guest Editors

Dear Colleagues,

This Special Issue focuses on myelodysplastic syndromes (MDS), chronic myeloproliferative neoplasms (MPN), and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). The Revised 4th Edition of the WHO Classification of Haematopoietic and Lymphoid Tissues has introduced many changes in the terminology and diagnostic approach of MDS and MDS/MPN, as well as recent knowledge regarding molecular and genetic alterations of MPN. Many questions remain unresolved and active research is ongoing in this field, and new clinicopathological entities and molecular-genetic findings have been recently described.

The purpose of this Special Issue is to offer recent studies focusing on the biology, diagnostic features, and treatment of chronic myeloid neoplasms. Original research articles and reviews are both welcome.

Dr. Luis Colomo
Dr. Xavier Calvo
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)